[1] Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol. 2007 Jan 26;555(2-3):115-21.
[2] Perez CI, Luis-Islas J, Lopez A, Diaz X, Molina O, Arroyo B, Moreno MG, Lievana EG, Fonseca E, Castañeda-Hernández G, Gutierrez R. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS One. 2024 Apr 24;19(4):e0300544.
[3] Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjödin A. The effect of tesofensine on appetite sensations. Obesity (Silver Spring). 2012 Mar;20(3):553-61.
[4] Pan Y, Liu J, Qi F. Identification of key candidate genes and molecular pathways in white fat browning: an anti-obesity drug discovery based on computational biology. Hum Genomics. 2019 Nov 7;13(1):55.
[5] Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig. 2008 Sep;5(3):142-7.
[6] Perez CI, Luis-Islas J, Lopez A, Diaz X, Molina O, Arroyo B, Moreno MG, Lievana EG, Fonseca E, Castañeda-Hernández G, Gutierrez R. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS One. 2024 Apr 24;19(4):e0300544.